Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS: In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. RESULTS: Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication. CONCLUSIONS: The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“(% [95% CI])† 44 (61 [49–72]) 4 (11 [3–25]) 12 (52 [31–73]) 1 (10 [0–45])”
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Not reported 1 (1) 1 (3) 1 (1) 1 (2) 2 (1)”
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“>ULN 15 (21) 7 (19) 24 (25) 11 (23) 35 (25)”
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 3×
“Stable disease 9 (12) 13 (35) 3 (13) 1 (10)”
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“M1b 22 (31) 8 (22) 27 (28) 12 (26) 39 (27)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 4×
“Increased lipase 12 (13) 8 (9) 2 (4) 1 (2)”
InfluentialSelf-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citation
Cited by
Items 801–900 of 1,008
First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
Bylicki, O., Barazzutti, H., Paleiron, N., Margery, J., Assié, J., & CHOUAID, C. (2019) · BioDrugs · doi:10.1007/s40259-019-00339-4 · Cited by 61
Kassi, E. N., Angelousi, A. G., Asonitis, N., Diamantopoulos, P. T., Anastasopoulou, A. N., Papaxoinis, G., Kokkinos, M., Giovannopoulos, I., Kyriakakis, G., Petychaki, F., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2533 · Cited by 63
Melanoma: An update on systemic therapies
Skudalski, L., Waldman, R. A., Kerr, P. E., & Grant-Kels, J. M. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.09.075 · Cited by 64
Nivolumab: A Review in Advanced Melanoma
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0442-6 · Cited by 64
Rajkumar, S., & Watson, I. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.195 · Cited by 57
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 57
Self-citationAdvanced stage melanoma therapies: Detailing the present and exploring the future
Luther, C. A., Swami, U., Zhang, J., Milhem, M. M., & Zakharia, Y. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.11.002 · Cited by 64
Keller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 58
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
Apalla, Z., Papageorgiou, C., Lallas, A., Delli, F. S., Fotiadou, C., Kemanetzi, C., & Lazaridou, E. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1101a155 · Cited by 72
“However, the incidence of severe cases is low [27-31].”
Lemaire, V., Shemesh, C. S., & Rotte, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02111-5 · Cited by 57
Management of infusion-related reactions in cancer therapy: strategies and challenges
Barroso, A., Estevinho, F., Hespanhol, V. P., Teixeira, E., Ramalho-Carvalho, J., & Araújo, A. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102922 · Cited by 85
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
Zheng, P., & Zhou, Z. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29325 · Cited by 60
de Geus, S. W. L., Evans, D. B., Bliss, L. A., Eskander, M. F., Smith, J. K., Wolff, R. A., Miksad, R. A., Weinstein, M. C., & Tseng, J. F. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.016 · Cited by 63
Gabani, P., Fischer-Valuck, B. W., Johanns, T. M., Hernandez-Aya, L. F., Keller, J. W., Rich, K. M., Kim, A. H., Dunn, G. P., Robinson, C. G., Chicoine, M. R., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.06.017 · Cited by 57
The Changing Clinical Spectrum of Hypophysitis
Chiloiro, S., Capoluongo, E., Tartaglione, T., Giampietro, A., Bianchi, A., Giustina, A., Pontecorvi, A., & Marinis, L. D. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.06.004 · Cited by 58
Abdel-Rahman, O., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., Schöb, O., Mannhart, M., & Oweira, H. (2017) · Clinical Oncology · doi:10.1016/j.clon.2016.11.007 · Cited by 55
Diagnosis and Management of Immune Checkpoint Inhibitor Colitis.
Hashash, J. G., Francis, F. F., & Farraye, F. A. (2021) · Europe PMC (PubMed Central) · Cited by 83
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
AACR Cancer Progress Report 2015
Baselga, J., Bhardwaj, N., Cantley, L. C., DeMatteo, R., DuBois, R. N., Foti, M., Gapstur, S. M., Hahn, W. C., Helman, L. J., Jensen, R. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1846 · Cited by 55
Gao, Y. J., Li, S., Xu, D., Chen, S., Cai, Y., Jiang, W., Zhang, X., Sun, J., Wang, K., Chang, B., et al. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0226-3 · Cited by 60
T cell exhaustion in cancer: Mechanisms and clinical implications
Wang, J., Xu, Y., Huang, Z., & Lu, X. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26645 · Cited by 60
Mahmood, S., Chen, C. L., Shapnik, N., Krishnan, U., Singh, H. S., & Makker, V. (2018) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2018.05.014 · Cited by 57
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
Teige, I., Mårtensson, L., & Frendéus, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00481 · Cited by 59
Ross, A. E., Hurley, P. J., Tran, P. T., Rowe, S. P., Benzon, B., Neal, T. O., Chapman, C. G., Harb, R., Milman, Y., Trock, B. J., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0176-8 · Cited by 58
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 62
“C) A. 0.2 B. 1.5 C. 0 A.+ B. 10–15 C. 3.0 Unresectable or metastatic melanoma (March 2011) Postow et al. (2015) [128] CheckMate-069 II Metastatic melanoma with no prior treatment A. Ipilimumab 3 mg/kg + nivolumab 1 mg/kg Q3wks followed by nivolumab 3 mg/kg Q2wks B. Ipilimumab 3 mg/kg + placebo…”
InfluentialInterventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value
Serritella, A. V., Strohbehn, G. W., Goldstein, D. A., Lichter, A. S., & Ratain, M. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1853 · Cited by 60
“In contrast, many patients achieve their maximal response in shorter periods of time or have a durable response despite early discontinuation due to side effects.(36) Although many irAEs occur in a dose-dependent manner within 3–6 months of therapy, others occur years later.”
Postow, M. A., Goldman, D. A., Shoushtari, A. N., Warner, A. B., Callahan, M. K., Momtaz, P., Smithy, J. W., Naito, E., Cugliari, M. K., Raber, V., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01570 · Cited by 61
Self-citationImmunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 61
“Monoclonal antibodies directed against immune checkpoint molecules, known as immune checkpoint inhibitors (ICIs), comprise the most advanced paradigm of immunotherapy in the clinical setting, managing to prolong overall survival of patients with melanoma [14-16], triple negative breast cancer [17], non-small cell lung…”
BackgroundImmune checkpoint inhibitors: a patent review (2010-2015)
Collin, M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1176150 · Cited by 58
Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma
Blasig, H., Bender, C., Hassel, J. C., Eigentler, T., Sachse, M., Hiernickel, J., Koop, A., Satzger, I., & Gutzmer, R. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000341 · Cited by 54
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development
Zhu, M. M. T., Dancsok, A. R., & Nielsen, T. O. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0750-1 · Cited by 55
Schermers, B., Franke, V., Rozeman, E. A., van de Wiel, B. A., Bruining, A., Wouters, M. W. J. M., van Houdt, W. J., ten Haken, B., Muller, S. H., Bierman, C., et al. (2019) · British journal of surgery · doi:10.1002/bjs.11168 · Cited by 55
Nivolumab Plus Ipilimumab in Non-Small-Cell Lung Cancer
Reck, M., Borghaei, H., & O'Byrne, K. J. (2019) · Future Oncology · doi:10.2217/fon-2019-0031 · Cited by 58
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
“As a monotherapy, the effect of ipilimumab is not as strong as that of the PD-1 antibody nivolumab (Opdivo) for resected stage III or IV melanoma and showed shorter survival and higher toxicity for patients than the PD-1 antibody pembrolizumab (Keytruda) (59, 60).”
BackgroundStatistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
Mick, R., & Chen, T. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0260 · Cited by 54
T-cell programming in pancreatic adenocarcinoma: a review
Seo, Y. D., & Pillarisetty, V. G. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.66 · Cited by 56
Lima, J. P. D. S. N., Georgieva, M., Haaland, B. A., & Lopes, G. D. L., Jr. (2017) · Cancer Medicine · doi:10.1002/cam4.1001 · Cited by 59
Integration of radiation and immunotherapy in breast cancer - Treatment implications
Ye, J. C., & Formenti, S. C. (2018) · The Breast · doi:10.1016/j.breast.2017.12.005 · Cited by 58
Tolba, M. F., & Omar, H. A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.005 · Cited by 59
Oncolytic viruses—immunotherapeutics on the rise
Keller, B. A., & Bell, J. C. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1453-9 · Cited by 64
Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy
Apostolova, P., Unger, S., von Bubnoff, D., Meiß, F., Becher, B., & Zeiser, R. (2020) · New England Journal of Medicine · doi:10.1056/nejmc1912274 · Cited by 52
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 61
“alone, regardless of BRAF mutations [128,129].”
BackgroundImmune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
Joseph, G. J., Johnson, D. B., & Johnson, R. W. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100505 · Cited by 58
Yamazaki, N., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Kiyohara, Y., Tsutsumida, A., Namikawa, K., Okuyama, R., Otsuka, Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2870-0 · Cited by 55
Immune checkpoint blockade: Releasing the brake towards hematological malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.11.003 · Cited by 56
Rekoske, B. T., Olson, B. M., & McNeel, D. G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1165377 · Cited by 57
A New VISTA on combination therapy for negative checkpoint regulator blockade
Deng, J., Mercier, I. L., Kuta, A., & Noelle, R. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0190-5 · Cited by 57
Hu‐Lieskovan, S., & Ribas, A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000246 · Cited by 55
Eckert, F., Jelas, I., Oehme, M., Huber, S. M., Sonntag, K., Welker, C., Gillies, S. D., Strittmatter, W., Zips, D., Handgretinger, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1323161 · Cited by 54
Clinical Development of PD-1 in Advanced Melanoma
Munhoz, R. R., & Postow, M. A. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000299 · Cited by 56
Self-citationAcquired resistance to cancer immunotherapy
Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 52
Wilcox, J. A., Ramakrishna, R. R., & Magge, R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.04.020 · Cited by 57
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
Garcia, C. A., El-Ali, A., Rath, T. J., Contis, L. C., Gorantla, V. C., Drappatz, J., & Davar, D. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0393-z · Cited by 52
Yao, L., Jia, G., Lu, L., Bao, Y., & Ma, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106628 · Cited by 56
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
“anti-CTLA-4 antibodies can increase response rates in some settings, but also significantly increases potential toxicity (Postow et al. 2015).”
BackgroundBrom, V. C., Burger, C., Wirtz, D. C., & Schildberg, F. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837645 · Cited by 57
Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 69
Tumour radiosensitivity is associated with immune activation in solid tumours
Ström, T., Harrison, L. B., Giuliano, A. R., Schell, M. J., Eschrich, S. A., Berglund, A., Fulp, W. J., Thapa, R., Coppola, D., Kim, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.001 · Cited by 55
Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer
Cohen, I., & Blasberg, R. G. (2017) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223417731565 · Cited by 69
Understanding heterogeneous tumor microenvironment in metastatic melanoma
Yan, Y., Leontovich, A. A., Gerdes, M. J., Desai, K., Dong, J., Sood, A., Santamaría-Pang, A., Mansfield, A. S., Chadwick, C. M., Zhang, R., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216485 · Cited by 58
Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function
Mullinax, J. E., Hall, M. S., Beatty, M. S., Weber, A. M., Sannasardo, Z., Svrdlin, T., Hensel, J. A., Bui, M. M., Richards, A. D., González, R., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000355 · Cited by 55
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
Boland, P., Pavlick, A. C., Weber, J., & Sandigursky, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000356 · Cited by 50
Self-citationMukhopadhyay, P., Ye, J., Anderson, K. M., Roychoudhury, S., Rubin, E. H., Halabi, S., & Chappell, R. J. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2666 · Cited by 59
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma
Zhou, Z., Chen, M.-J. M., Luo, Y., Mojumdar, K., Peng, X., Chen, H., Kumar, S. V., Akbani, R., Lu, Y., & Liang, H. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.012 · Cited by 53
“Many cancer patients, even those with advanced refractory cancers, show beneficial clinical responses, sometimes long-lasting ones, to checkpoint inhibitors targeting programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) (Hodi et al., 2010; Postow et al., 2015; Top…”
BackgroundSide-effects of checkpoint inhibitor-based combination therapy
Kourie, H. R., & Klastersky, J. A. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000295 · Cited by 50
Immune-mediated respiratory adverse events of checkpoint inhibitors
Tabchi, S., Messier, C., & Blais, N. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000291 · Cited by 50
Treatment of brain metastases in the modern genomic era
Dagogo‐Jack, I., Gill, C. M., Cahill, D. P., Santagata, S., & Brastianos, P. K. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.011 · Cited by 56
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma
Mouw, K. W., Cleary, J. M., Reardon, B. M., Pike, J. W., Braunstein, L. Z., Kim, J., Amin‐Mansour, A., Miao, D., Damish, A. W., Chin, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2017 · Cited by 51
Self-citationHighly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
Saito, H., Kono, Y., Murakami, Y., Shishido, Y., Kuroda, H., Matsunaga, T., Fukumoto, Y., Osaki, T., Ashida, K., & Fujiwara, Y. (2018) · Anticancer Research · doi:10.21873/anticanres.12197 · Cited by 57
Immune checkpoint molecules in acute myeloid leukaemia: managing the double‐edged sword
Hobo, W. A., Hutten, T. J. A., Schaap, N. P., & Dolstra, H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15078 · Cited by 59
Barutello, G., Rolih, V., Arigoni, M., Tarone, L., Conti, L., Quaglino, E., Buracco, P., Cavallo, F., & Riccardo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030799 · Cited by 76
Management of immune related adverse events induced by immune checkpoint inhibition
Teufel, A., Zhan, T., Härtel, N., Bornschein, J., Ebert, M. P., & Schulte, N. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.018 · Cited by 56
Chalmers, A. W., Patel, S. B., Boucher, K. M., Cannon, L. A., Esplin, M., Luckart, J. B., Graves, N., Duren, T. V., & Akerley, W. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00658-0 · Cited by 53
Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
Pezo, R. C., Wong, M., & Martin, A. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819870911 · Cited by 55
CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
Liu, F., Huang, J., He, F., Ma, X., Fan, F., Meng, M., Yang, Z., & Zhang, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-66806-z · Cited by 54
Nivolumab plus ipilimumab in the treatment of advanced melanoma
Tsai, K. K., & Daud, A. I. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0219-0 · Cited by 48
Sachpekidis, C., Larribère, L., Kopp‐Schneider, A., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2279-9 · Cited by 53
Xu, X., Huang, Z., Zheng, L., & Fan, Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31252 · Cited by 50
Chan, K., Glenny, A., Weldon, J. C., Furness, S., Worthington, H. V., & Wakeford, H. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010341.pub2 · Cited by 64
Yusuf, M. B., Amsbaugh, M. J., Burton, E., Chesney, J. A., & Woo, S. Y. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.01.101 · Cited by 50
Self-citationAn Expanding Role for Immunotherapy in Colorectal Cancer
Bever, K. M., & Le, D. T. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0037 · Cited by 51
miRNAs, Melanoma and Microenvironment: An Intricate Network
Romano, G., & Kwong, L. N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112354 · Cited by 51
Faiena, I., Cummings, A. L., Crosetti, A. M., Pantuck, A. J., Chamie, K., & Drakaki, A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s141491 · Cited by 53
Cardiotoxicities associated with immune checkpoint inhibitors
Yang, S., & Asnani, A. H. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.002 · Cited by 50
Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer
Park, R., Williamson, S. K., Kasi, A., & Saeed, A. (2018) · Anticancer Research · doi:10.21873/anticanres.12891 · Cited by 53
Lin, W., Chen, M., Hong, L., Zhao, H., & Chen, Q. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00532 · Cited by 56
Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer
Wang, H., Wang, S., Huang, M.-C., Liang, X., Tang, Y.-J., & Tang, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00498 · Cited by 61
“2% (16/72) of patients in the combination group, whereas in the ipilimumab group, none were reported to receive complete responses (38).”
BackgroundNovel Biomarkers for Personalized Cancer Immunotherapy
Shindo, Y., Hazama, S., Tsunedomi, R., Suzuki, N., & Nagano, H. (2019) · Cancers · doi:10.3390/cancers11091223 · Cited by 52
“A combination therapy of ICIs can improve the response rate, but is associated with increased immune-related toxicity and treatment costs [20].”
BackgroundDDR1 promotes breast tumor growth by suppressing antitumor immunity
Zhong, X., Zhang, W., & Sun, T. (2019) · Oncology Reports · doi:10.3892/or.2019.7338 · Cited by 63
“T lymphocytes (CTL) and blockade of immune-suppressive checkpoint molecules (3-8).”
BackgroundHuang, R.-Z., Jing, X.-T., Huang, X., Pan, Y.-M., Fang, Y., Liang, G.-B., Liao, Z., Wang, H., Chen, Z., & Zhang, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01386 · Cited by 48
Lau, D., Garçon, F., Chandra, A., Lechermann, L. M., Aloj, L., Chilvers, E. R., Corrie, P. G., Okkenhaug, K., & Gallagher, F. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01514 · Cited by 55
Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer
Luo, M., Wang, F., Zhang, H., To, K. K. W., Wu, S., Chen, Z., Liang, S., & Fu, L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0200-4 · Cited by 59
Lamb, L. S., Sim, H., & McCormack, A. I. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576027 · Cited by 49
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 53
Managing Adverse Events With Immune Checkpoint Agents
Dadu, R., Zobniw, C., & Diab, A. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000186 · Cited by 48
Guo, X.-J., Lu, J., Zeng, H., Zhou, R., Sun, Q., Yang, G., Pei, Y.-Z., Meng, X., Shen, Y., Zhang, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705378 · Cited by 53
“Preliminary results of a clinical study report that the combination of the anti-CTLA-4 antibody ipilimumab and anti-PD1 antibody nivolumab elevated the objective response rate (ORR) and the progression-free survival of patients with BRAF metastatic or unresectable melanoma (15).”
BackgroundThe immune-related role of beta-2-microglobulin in melanoma
Wang, C., Wang, Z., Yao, T., Zhou, J., & Wang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.944722 · Cited by 58
“1 B2M alterations induce ICI resistance while ICIs promote B2M mutations Immune checkpoint blockade (ICB) therapy is designed to target immune checkpoint receptors on tumors and immune cells, such as programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1) or cytotoxic associated lymphocyte antigen-4 (CTLA-4)…”
BackgroundHistone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
Gallagher, S. J., Tiffen, J. C., & Hersey, P. (2015) · Cancers · doi:10.3390/cancers7040870 · Cited by 51
Advances in the treatment of newly diagnosed glioblastoma
Theeler, B. J., & Gilbert, M. R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0536-8 · Cited by 51
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 62
Metadata
- Authors
- Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D., & Hodi, F. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Université Paris-Sud (FR)
- Beth Israel Deaconess Medical Center (US)
- From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) — all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) — all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D....
- Prisma Health (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-21
- Volume
- 372
- Issue
- 21
- Pages
- 2006-2017
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5744258
- OpenAlex
- W2128758225
- Cited by
- 2,781
- References
- 28
- Citations by year
- 2026: 53 · 2025: 91 · 2024: 131 · 2023: 175 · 2022: 174 · 2021: 206 · 2020: 261 · 2019: 277 · 2018: 372 · 2017: 449 · 2016: 402 · 2015: 183
- FWCI
- 204.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, metastatic melanoma, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, objective response rate, progression-free survival, BRAF V600 mutation, immune-related adverse events, first-line therapy, dose escalation, complete response, duration of response
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Disease-Free Survival, Tumor Burden, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.